- Home
- NFE vs CNTA Comparison
NFE vs CNTA Comparison
Compare NFE & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFE
- CNTA
- Stock Information
- Founded
- NFE 2014
- CNTA 2020
- Country
- NFE United States
- CNTA United Kingdom
- Employees
- NFE N/A
- CNTA N/A
- Industry
- NFE Oil/Gas Transmission
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- NFE Utilities
- CNTA Health Care
- Exchange
- NFE Nasdaq
- CNTA Nasdaq
- Market Cap
- NFE 1.6B
- CNTA 1.8B
- IPO Year
- NFE 2019
- CNTA 2021
- Fundamental
- Price
- NFE $6.27
- CNTA $12.36
- Analyst Decision
- NFE Buy
- CNTA Strong Buy
- Analyst Count
- NFE 6
- CNTA 10
- Target Price
- NFE $15.17
- CNTA $26.11
- AVG Volume (30 Days)
- NFE 6.5M
- CNTA 663.9K
- Earning Date
- NFE 05-12-2025
- CNTA 05-20-2025
- Dividend Yield
- NFE 3.26%
- CNTA N/A
- EPS Growth
- NFE N/A
- CNTA N/A
- EPS
- NFE N/A
- CNTA N/A
- Revenue
- NFE $2,354,111,000.00
- CNTA N/A
- Revenue This Year
- NFE $6.75
- CNTA N/A
- Revenue Next Year
- NFE $24.11
- CNTA N/A
- P/E Ratio
- NFE N/A
- CNTA N/A
- Revenue Growth
- NFE N/A
- CNTA N/A
- 52 Week Low
- NFE $4.72
- CNTA $7.75
- 52 Week High
- NFE $29.11
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- NFE 48.70
- CNTA 43.78
- Support Level
- NFE $5.50
- CNTA $11.88
- Resistance Level
- NFE $6.26
- CNTA $14.39
- Average True Range (ATR)
- NFE 0.41
- CNTA 0.79
- MACD
- NFE 0.25
- CNTA 0.01
- Stochastic Oscillator
- NFE 95.24
- CNTA 29.18
About NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.